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Non-coding RNAs have received considerable attention within the cardiovascular research field over 
the last decade, especially the short non-coding RNA class commonly termed as microRNA (miRNA, 
miR). MicroRNAs are approximately 18–22 nucleotides in length and predicted to post-
transcriptionally control 60-90% of protein-coding genes through inhibiting translation or promoting 
degradation of target messenger (m)RNA 1 2. Importantly, a single microRNA can potentially target a 
large number of genes 1, explaining why there are far less microRNAs than target genes, and there is 
evidence that multiple targets exist within the same functional networks. As such, mature microRNA 
possess the potential to play a central role in regulating cellular function, while their spatial and 
temporal expression patterns provide clues to their function 1 2. Accordingly, microRNAs are 
considered fine-tuners of gene and protein expression profiles during the progression of 
atherosclerosis, a proposition supported by human pathological studies alongside findings from 
diseased animal models where select microRNA function or expression have been modulated 3. Such 
approaches identified multiple microRNAs which may serve as therapeutic targets for the prevention 
of clinical events associated with atherosclerotic plaque destabilisation, such as myocardial infarction 
and stroke 3.  
However, a marked proportion of patients who suffer a major adverse cardiovascular event (MACE) 
will have been previously asymptomatic, and even patients with confirmed clinically-relevant 
atherosclerosis and receiving optimal medical therapy, will experience additional future clinical events 
4. There is consequently a pertinent need for biomarkers which can readily inform a patient’s risk of 
experiencing atherosclerotic plaque rupture and a subsequent clinical event. Relatedly, stable 
microRNAs have been detected within circulating blood, either conjugated with lipoproteins, 
packaged within extracellular vesicles (such a microvesicles and exosomes), or as a result of cell 
leakage during cell injury or apoptosis 5. Moreover, circulating microRNA levels are associated with 
cardiovascular disease risk factors including hyperlipidaemia, and there are examples of specific 
miRNAs correlating with atherosclerosis and myocardial infarction 3. 
In this issue of Cardiovascular Research, Escate and colleagues 6 examine if microRNA can be deployed 
as predictors of atherosclerotic plaque progression and related clinical events in patients with familial 
hypercholesterolaemia (FH), although potentially applicable to all individuals with atherosclerosis. The 
authors profiled microRNAs within exosomes isolated from circulating blood of patients with FH which 
had suffered a major adverse cardiovascular event (MACE) during an 8 year follow-up, alongside 
relatives without genetic diagnosis of FH and MACE, all participants within the SAFEHEART cohort 7. 
This discovery approach identified 42 differentially expressed microRNAs which were subsequently 
subjected to pathway analysis and revealed 17 exosome-isolated microRNAs which were related to 
bioinformatically-defined atherosclerosis processes, such as ‘inflammatory response’. Further RT-PCR 
validation of the 17 identified microRNAs was undertaken within exosomes, microvesicles, and plasma 
from a larger cohort of patients. This validation stage elucidated 9 microRNAs which were consistently 
increased within the plasma and exosome fraction of FH patients which had experienced MACE during 
an 8-year follow-up compared to non-FH individuals with no evidence of MACE. Due to the correlation 
between plasma microRNA concentrations and those detected within exosomes, the authors propose 
plasma microRNA levels can serve as a surrogate for exosome microRNA content. 
Subsequently, the 9 identified microRNAs were retrospectively compared within the plasma of FH 
patients with MACE, without MACE, and non-FH/non-MACE individuals subjected to 8-year follow-up. 
While this refinement stage revealed elevated expression of all 9 microRNAs were discriminatory for 
FH patients, only significantly increased miR-133a plasma levels identified FH patients experiencing 
MACE. Further analysis supported the predictive power of miR-133a (alongside miR-200c and miR-
339-3p) for incidence of future cardiovascular events, including sudden death, fatal and non-fatal 
myocardial infarction, unstable angina and cerebrovascular incidents, during 5, 8, and 10-year follow-
up periods after entering the SAFEHEART cohort, and independent of other cardiovascular risk factors. 
The authors next deployed in silico analysis to identify 923 potential target genes of miR-133a, 42 of 
which were delineated in a biased fashion due to their association with cardiovascular disease related 
processes identified using bioinformatics software analysis. Through further in silico analysis, the 
transcription factors FOXL2 and DNAJB6 alongside the membrane receptor CD130 (a unit of the IL-6 
receptor complex) were predicated, implying miR-133a regulates the Wnt/β-catenin and IL-6 
signalling pathways, respectively. Substantiating these propositions, the authors demonstrated 
increasing miR-133a exogenously in primary human macrophages or microvascular endothelial cells 
elevated mRNA expression of both CTNNB1 and IL6R. 
The study by Escate and colleagues 6 affords a further microRNA to add to the armamentarium of 
potential biomarkers for atherosclerosis progression and risk of an associated clinical event (as 
summarised within Figure and reviewed by 3). Although the present study focussed on FH patients 
(the most common genetic disorder associated with premature atherosclerosis-related cardiovascular 
disease), the findings have likely broader utility to all individuals with atherosclerosis. Supporting 
evidence is provided by similar microRNA profiling clinical studies revealing that miR-133a plasma 
levels are increased in patients with angiographic-defined coronary artery disease (CAD) when 
compared to healthy subjects 8 and those experiencing an acute myocardial infarction (AMI) relative 
to CAD patients without an AMI or healthy individuals 9. In addition, intra-plaque concentrations of 
miR-133a are increased in carotid lesions deemed symptomatic relative to asymptomatic plaques 10, 
indicating that elevated circulating levels of miR-133a are likely to derive from vulnerable and 
ruptured plaques.  
However, miR-133a is considered a cardiac-specific microRNA primarily expressed within 
cardiomyocytes 11, and the elevated levels detected post myocardial infarction are speculated to 
originate from injured and dying cardiomyocytes 9, 12, 13. While in accordance with the study from 
Escate et al 6, circulating levels of miR-133a display prognostic value for all-cause mortality in CAD 
patients which present with AMI, such predictive capacity correlated with high-sensitivity troponin T 
levels and therefore the extent of myocardial injury 12. Escate and colleagues do not clarify the cellular 
or tissue source of the elevated miR-133a detected within their study or define if the association 
between raised miR-133a levels and future MACE are causal. While they infer the increase is plaque-
dependent, the above-mentioned studies argue otherwise and even suggest microRNAs released from 
the damaged myocardium after an AMI track to coronary plaques to exert subsequent biological 
effects 13. An alternate hypothesis is that miR-133a is released from coronary plaques after rupture 
(not causal) and during their subsequent healing, a phenomenon known to be prevalent within culprit 
coronary atherosclerotic lesions 14. This possibility would question the applicability of miR-133a as a 
therapeutic target, as retarding vascular smooth muscle cell growth and ensuing plaque healing, 
including the reformation of the protective fibrous cap, may accelerate another adverse clinical event. 
Indeed, 13% of individuals within the SAFEHEART cohort have evidence of previous clinical premature 
atherosclerosis 7, while mouse studies have revealed a central role for miR-133a in vascular smooth 
muscle cell growth 15. 
 
The current study from Escate and colleagues alongside other research reveals miR-133a as a potential 
surrogate marker of previous plaque rupture and subsequent AMI, representing a vulnerable patient 
with a preponderance for future clinical events, particularly those with overt risk factors such as FH. 
Additional studies are warranted to identify the source of circulating miR-133a and its potential distal 
biological function, particularly if it is to be considered as a therapeutic target for cardiovascular 
disease prevention. Finally, larger profiling studies to substantiate miR-133a as a bona-fide biomarker 
for disease progression should be encouraged, alongside other circulating microRNAs proposed as 
prognostic biomarkers (see Figure).   
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Figure title: MicroRNA expression within circulating blood of patients with atherosclerosis.  
This diagram illustrates the elevated microRNAs identified through profiling approaches within 
circulating plasma samples (including exosomes) and peripheral blood mononuclear cells (PBMCs) of 
patients with clinical atherosclerosis. Blue-filled box indicates intra-plaque cellular sources of 
circulating microRNA. Green-filled box signifies the forms in which circulating microRNA are 
packaged and potential other tissue sources. Line-coloured boxes indicate the patient cohorts from 
within which the associated upregulated microRNAs were identified. Yellow highlighting shows 
elevated miR-133a has been verified in an independent study, while microRNA with grey highlighting 
have been independently reported to be up- and down-regulated. 
